Hypocalcemia following denosumab in osteoporosis: Incidence and risk factors in a Saudi cohort

Key Points

• Hypocalcemia incidences were significant in patients receiving denosumab, indicating a need for monitoring.
• The study identified key risk factors such as baseline calcium levels and age affecting hypocalcemia incidence.
• Observational analysis across a Saudi cohort revealed important trends in osteoporosis treatment outcomes.
• The findings highlight the importance of monitoring patients on denosumab for potential complications.